AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Markets JNJ Johnson & Johnson Reports Promising Phase 1 Results For Erda-iDRS In Early-Stage Bladder Cancer March 13, 2026 — 10:34 pm EDT Written by RTTNews.com for RTTNews -> (RTTNews) - Johnson & Johnson (JNJ) announced new data from an open-label, multicenter Phase 1 study evaluating Erda-iDRS, an investigational intravesical drug-releasing system with erdafitinib, in patients with non-muscle-invasive bladder cancer (NMIBC) harboring select FGFR alterations. Results were presented at the European Association of Urology (EAU) 2026 Annual Meeting. FGFR alterations occur in approximately 70% of intermediate-risk and 40% of high-risk NMIBC tumors, making them an important therapeutic target. Erda-iDRS is designed to deliver prolonged release of erdafitinib directly into the bladder over three months, aiming to provide localized treatment while minimizing systemic exposure. In the intermediate-risk cohort, Erda-iDRS achieved an 89% complete response rate, with a median duration of response of 18 months. Nearly half of patients remain in follow-up, underscoring the durability of benefit. In the high-risk cohort, median recurrence-free survival reached 20 months, with ongoing follow-up in 31% of patients. Treatment was generally well tolerated, with most adverse events limited to local effects such as hematuria (32%) and dysuria (22%). Grade 3 or higher events occurred in 5% of patients, and discontinuations due to adverse events were infrequent. Pharmacokinetic analyses confirmed sustained drug levels in urine with minimal systemic exposure. These findings support continued development of Erda-iDRS, with Phase 2 and Phase 3 studies underway to further evaluate its potential as the first targeted treatment for early-stage bladder cancer. Johnson & Johnson closed Friday regular trading at $241.52, down $0.52 or 0.21%. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags Markets RTTNews Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. More articles by this source -> Stocks mentioned JNJ More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.